Inflammatory processes have been identified as key mediators of ischemia-reperfusion injury in ST-segment elevation myocardial infarction (STEMI). They add damage to the myocardium and are associated with clinical adverse events (heart failure and cardiovascular death) and poor myocardial recovery. Colchicine is a well-known alkaloid with potent anti-inflammatory properties. In a proof-of-concept phase II trial, colchicine has been associated with a significant 50% reduction of infarct size (assessed by creatine kinase levels) in comparison to placebo in acute STEMI patients referred for primary percutaneous coronary intervention (PPCI). The Colchicine in STEMI Patients Study (COVERT-MI) is an ongoing confirmative prospective, multicenter, randomized, double-blind trial testing whether a short course oral treatment with colchicine versus placebo decreases myocardial injury in patients presenting with STEMI referred for PPCI. Adult patients, with a first STEMI episode and an initial TIMI flow ≤1, referred for PPCI, will be randomized (n = 194) in a 1:1 ratio to receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. treatment during 5 days or matching placebo. The primary endpoint will be the reduction in infarct size as assessed by cardiac magnetic resonance at 5 ± 2 days between both groups. The main secondary endpoints will be tested between groups in hierarchical order with left ventricular ejection fraction at 5 days, microvascular obstruction presence at 5 days, and absolute adverse left ventricular remodeling between 5 days and 3 months. This academic study is being financed by a grant from the French Ministry of Health (PHRCN-16-0357). Results from this study will contribute to a better understanding of the complex pathophysiology underlying myocardial injury after STEMI. The present study describes the rationale, design, and methods of the trial.

1.
Blin
P
,
Philippe
F
,
Bouée
S
,
Laurendeau
C
,
Torreton
E
,
Gourmelin
J
, et al
Outcomes following acute hospitalised myocardial infarction in France: an insurance claims database analysis
.
Int J Cardiol
.
2016
;
219
:
387
93
.
2.
Ibanez
B
,
James
S
,
Agewall
S
,
Antunes
MJ
,
Bucciarelli-Ducci
C
,
Bueno
H
, et al
2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
.
Eur Heart J
.
2018
;
39
:
119
77
.
3.
Yancy
CW
,
Jessup
M
,
Bozkurt
B
,
Butler
J
,
Casey
DE
,
Colvin
MM
, et al
2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America
.
J Am Coll Cardiol
.
2016
;
68
(
13
):
1476
88
. .
4.
Eitel
I
,
de Waha
S
,
Wöhrle
J
,
Fuernau
G
,
Lurz
P
,
Pauschinger
M
, et al
Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction
.
J Am Coll Cardiol
.
2014
;
64
(
12
):
1217
26
. .
5.
Gibbons
RJ
,
Valeti
US
,
Araoz
PA
,
Jaffe
AS
.
The quantification of infarct size
.
J Am Coll Cardiol
.
2004
;
44
(
8
):
1533
42
. .
6.
Lønborg
J
,
Vejlstrup
N
,
Kelbæk
H
,
Holmvang
L
,
Jørgensen
E
,
Helqvist
S
, et al
Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study
.
Eur Heart J Cardiovasc Imaging
.
2013
;
14
(
4
):
387
95
. .
7.
Puymirat
E
,
Simon
T
,
Steg
PG
,
Schiele
F
,
Guéret
P
,
Blanchard
D
, et al
Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction
.
JAMA
.
2012
;
308
(
10
):
998
1006
. .
8.
Bouleti
C
,
Mewton
N
,
Germain
S
.
The no-reflow phenomenon: state of the art
.
Arch Cardiovasc Dis
.
2015
;
108
(
12
):
661
74
. .
9.
Niccoli
G
,
Cosentino
N
,
Minelli
S
,
Cataneo
L
,
Crea
F
.
Microvascular obstruction after primary percutaneous coronary intervention: pathogenesis, diagnosis and prognostic significance
.
Curr Vasc Pharmacol
.
2013
;
11
(
2
):
245
62
. .
10.
Cung
TT
,
Morel
O
,
Cayla
G
,
Rioufol
G
,
Garcia-Dorado
D
,
Angoulvant
D
, et al
Cyclosporine before PCI in patients with acute myocardial infarction
.
N Engl J Med
.
2015
;
373
(
11
):
1021
31
. .
11.
Heusch
G
.
Critical issues for the translation of cardioprotection
.
Circ Res
.
2017
;
120
(
9
):
1477
86
. .
12.
Deftereos
S
,
Giannopoulos
G
,
Angelidis
C
,
Alexopoulos
N
,
Filippatos
G
,
Papoutsidakis
N
, et al
Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study
.
Circulation
.
2015
;
132
(
15
):
1395
403
. .
13.
Savoye
C
,
Equine
O
,
Tricot
O
,
Nugue
O
,
Segrestin
B
,
Sautière
K
, et al
Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group)
.
Am J Cardiol
.
2006
;
98
(
9
):
1144
9
. .
14.
Vauchot
F
,
Ben Bouallègue
F
,
Hedon
C
,
Piot
C
,
Roubille
F
,
Mariano-Goulart
D
.
Assessment of the area at risk after acute myocardial infarction using 123I-MIBG SPECT: comparison with the angiographic APPROACH-score
.
J Nucl Cardiol
.
2018
;
25
(
2
):
572
80
. .
15.
Doherty
JU
,
Kort
S
,
Mehran
R
,
Schoenhagen
P
,
Soman
P
,
Dehmer
GJ
, et al
ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease: a report of the American college of cardiology appropriate use criteria task force, American association for thoracic surgery, American heart association, American society of echocardiography, American society of nuclear cardiology, heart rhythm society, society for cardiovascular angiography and interventions, society of cardiovascular computed tomography, society for cardiovascular magnetic resonance, and the society of thoracic surgeons
.
J Am Coll Cardiol
.
2019
;
73
(
4
):
488
516
. .
16.
Liebetrau
C
,
Hoffmann
J
,
Dörr
O
,
Gaede
L
,
Blumenstein
J
,
Biermann
H
, et al
Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction
.
Circ Res
.
2015
;
116
(
5
):
867
75
. .
17.
NG
.
Frangogiannis: the inflammatory response in myocardial injury, repair, and remodelling
.
Nat Rev Cardiol
.
2014
;
11
:
255
65
.
18.
Kaminski
KA
,
Bonda
TA
,
Korecki
J
,
Musial
WJ
.
Oxidative stress and neutrophil activation: the two keystones of ischemia/reperfusion injury
.
Int J Cardiol
.
2002
;
86
(
1
):
41
59
. .
19.
Anzai
T
.
Post-infarction inflammation and left ventricular remodeling: a double-edged sword
.
Circ J
.
2013
;
77
(
3
):
580
7
. .
20.
Liehn
EA
,
Postea
O
,
Curaj
A
,
Marx
N
.
Repair after myocardial infarction, between fantasy and reality: the role of chemokines
.
J Am Coll Cardiol
.
2011
;
58
(
23
):
2357
62
. .
21.
Elgendy
IY
,
Mahmoud
AN
,
Kumbhani
DJ
,
Bhatt
DL
,
Bavry
AA
.
Complete or culprit-only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention: a pairwise and network meta-analysis of randomized trials
.
JACC Cardiovasc Interv
.
2017
;
10
(
4
):
315
24
. .
22.
Seropian
IM
,
Toldo
S
,
Van Tassell
BW
,
Abbate
A
.
Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction
.
J Am Coll Cardiol
.
2014
;
63
(
16
):
1593
603
. .
23.
Davidson
SM
,
Ferdinandy
P
,
Andreadou
I
,
Bøtker
HE
,
Heusch
G
,
Ibáñez
B
, et al
Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week
.
J Am Coll Cardiol
.
2019
;
73
:
89
99
.
24.
Rout
A
,
Tantry
US
,
Novakovic
M
,
Sukhi
A
,
Gurbel
PA
.
Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction
.
Expert Opin Pharmacother
.
2020 Oct
;
21
(
15
):
1851
65
.
25.
Nuki
G
.
Colchicine: its mechanism of action and efficacy in crystal-induced inflammation
.
Curr Rheumatol Rep
.
2008
;
10
(
3
):
218
27
. .
26.
Bakhta
O
,
Blanchard
S
,
Guihot
AL
,
Tamareille
S
,
Mirebeau-Prunier
D
,
Jeannin
P
, et al
Cardioprotective role of colchicine against inflammatory injury in a rat model of acute myocardial infarction
.
J Cardiovasc Pharmacol Ther
.
2018
;
23
(
5
):
446
55
. .
27.
Tardif
JC
,
Kouz
S
,
Waters
DD
,
Bertrand
OF
,
Diaz
R
,
Maggioni
AP
, et al
Efficacy and safety of low-dose colchicine after myocardial infarction
.
N Engl J Med
.
2019
;
381
(
26
):
2497
505
. .
28.
Bouabdallaoui
N
,
Tardif
JC
,
Waters
DD
,
Pinto
FJ
,
Maggioni
AP
,
Diaz
R
, et al
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
.
Eur Heart J
.
2020 Nov 7
;
41
(
42
):
4092
9
.
29.
Nidorf
SM
,
Fiolet
ATL
,
Mosterd
A
,
Eikelboom
JW
,
Schut
A
,
Opstal
TSJ
, et al
Colchicine in patients with chronic coronary disease
.
N Engl J Med
.
2020 Nov
;
383
(
19
):
1838
47
.
30.
Samuel
M
,
Tardif
JC
,
Khairy
P
,
Roubille
F
,
Waters
DD
,
Grégoire
JC
, et al
Cost-effectiveness of low-dose colchicine after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT)
.
Eur Heart J Qual Care Clin Outcomes
.
2020 May 14
;
qcaa045
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.